Get the Daily Brief
Latest Biotech News
SARS-CoV-2 Host Protein Targets: New Avenue for Pan-Coronavirus Antivirals
Scientists at Scripps Research utilized a genome-wide siRNA screening to identify dozens of human host proteins essential for SARS-CoV-2 replication and late infection stages. Their work revealed...
Bioinformatics Breakthrough: High-Throughput Antibody Synthesis Accelerates Therapeutic Discovery
Researchers at the University of Illinois Urbana-Champaign have developed oPool+ display, a scalable platform integrating oligonucleotide pool synthesis and mRNA display to synthesize and...
Gilead Sciences Expands Biologics Capacity with New State-of-the-Art Biomanufacturing Center
Gilead Sciences has broken ground on a 180,000-square-foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City campus. This digitally enabled facility will...
FDA Accelerates Transparency on Drug Rejection Letters
The U.S. Food and Drug Administration (FDA) has taken a decisive step toward transparency by committing to publish complete response letters (CRLs) to drugmakers promptly after issuance. Following...
Atlas Venture Raises $400M to Support Biotech Startups
Atlas Venture, a leading biotech investment firm, secured $400 million for its third Opportunity Fund aimed at financing growth-stage companies within its portfolio. This strategic fund targets...
BioNTech and DualityBio Achieve Phase III Breast Cancer ADC Success
BioNTech SE and its partner Duality Biologics announced a Phase III interim analysis showing that their HER2-targeting antibody-drug conjugate (trastuzumab pamirtecan) met the primary endpoint of...
Groundbreaking Allogeneic CAR T Therapy for Multiple Sclerosis
Clinicians at the University of Nebraska have pioneered a first-of-its-kind treatment for multiple sclerosis (MS) using an off-the-shelf allogeneic CAR T-cell therapy, azercabtagene zapreleucel...
Innovative AI-Driven Oncology Diagnostics from Imagene
Imagene, a Miami-based precision oncology diagnostics company, is advancing AI-powered technologies to enhance cancer treatment decision-making. Leveraging an Oncology Intelligence foundation...
Artificial Sweetener Sucralose Linked to Reduced Cancer Immunotherapy Efficacy
A collaborative study led by the University of Pittsburgh uncovered that consumption of the artificial sweetener sucralose (marketed as Splenda) may impair patients’ responses to immune checkpoint...
MD Anderson Cancer Center Highlights Multifaceted Breakthroughs in Oncology
The University of Texas MD Anderson Cancer Center reported significant advances across multiple cancer types including pancreatic, colorectal, kidney, breast, stomach, and testicular tumors....
Novartis Expands Cardiovascular RNA Therapeutics with $160 Million Argo Biopharma Deal
Novartis has entered a multi-asset licensing and option agreement with Argo Biopharma, valued up to $5.2 billion, to access Argo’s siRNA cardiovascular drug candidates. The upfront payment totals...
Groundbreaking Insights into Estrogen’s Protective Role in Kidney Disease
A study published in Science by Romagnani and colleagues has elucidated how estrogen signaling enhances the regenerative capacity of podocytes, critical kidney filtering cells, in females. This...
Decoding Human Proteins Critical for SARS-CoV-2 Replication and Therapeutic Targeting
Researchers at Scripps Research performed a global siRNA screen identifying key human host factors essential for SARS-CoV-2’s replication cycle. The study differentiated proteins used in early and...
FDA Embraces Transparency with Real-Time Release of Drug Rejection Letters
The U.S. Food and Drug Administration (FDA) has initiated a major policy shift by committing to publish complete response letters (CRLs)—official documents explaining drug application...
Radiance Biopharma Signs $1B Deal for Bispecific Cancer Antibody-Drug Conjugate
Radiance Biopharma has entered an agreement potentially worth up to $1.165 billion for global rights to a bispecific nanobody antibody-drug conjugate (ADC) developed by Novatim Immune...
Breakthrough in Oncolytic Virus and Immunotherapy Synergies Advances Cancer Treatments
Emerging cancer treatments increasingly leverage genetically engineered oncolytic viruses that selectively infect and destroy tumor cells while simultaneously activating anti-tumor immune...
Atlas Venture Closes $400 Million Later-Stage Fund for Biotech Portfolio Growth
Atlas Venture, a prominent biotech investment firm, secured $400 million for its third Opportunity Fund aimed at bolstering its portfolio of drug startup companies. The fund targets seed-led...
Innovative AI Platform Imagene Leverages Oncology Intelligence to Guide Cancer Therapy
Imagene is pioneering the use of AI-powered foundation models trained on over 1.5 million biopsy images across 40 tissue types to enhance precision oncology. Their Oncology Intelligence (OI)...
UC San Diego Finds Spaceflight Accelerates Aging of Human Stem Cells Impacting Health
Researchers at the University of California San Diego discovered that spaceflight conditions foster accelerated aging in human hematopoietic stem and progenitor cells (HSPCs), key to blood and...
BioNTech and Duality Biologics Announce Phase 3 Breast Cancer ADC Trial Success
BioNTech and partner Duality Biologics reported that their HER2-targeting antibody-drug conjugate (ADC), trastuzumab pamirtecan, achieved the primary endpoint of progression-free survival in a...